P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 7, 2009, Pages 493-499

  Brozoek, Jacek ^a   Bryl, Ewa ^a   Płoszyńska, Anna ^a   Balcerska, Anna ^a   Witkowski, Jacek M ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Acute lymphoblastic eukemia; Children; Multidrug resistance; P glycoprotein; Prognostic factor

Indexed keywords

GLYCOPROTEIN P; LACTATE DEHYDROGENASE; RHODAMINE; VERAPAMIL; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLAST CELL; CANCER SUSCEPTIBILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATOMEGALY; HUMAN; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SCHOOL CHILD; SPLENOMEGALY; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; INFANT; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; P-GLYCOPROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 67650330816     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181a974b3     Document Type: Article

References (32)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese Hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-162.
2. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glikoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 1993;81:2394-2398.
3. Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer. 1994;70:1144-1149.
4. Ivy SP, Olshefski RS, Taylor BJ, et al. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. Blood. 1996;88: 309-318.
5. Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol. 1999;105:676-683.
6. De Moerloose B, Swerts K, Benoit Y, et al. The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2003;20:381-391.
7. Casale F, D'Angelo V, Addeo R, et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep. 2004;12:1201-1207.
8. Valera ET, Scrideli CA, Queiroz RG, et al. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J. 2004;122:166-171.
9. Kanerva J, Tiirikainen MI, Makipernaa A, et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up. Pediatr Hematol Oncol. 2001;18:27-36.
10. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85:711-721.
11. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998;91: 2092-2098.
12. Olson DP, Taylor BJ, La M, et al. The prognostic significance of p-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the children's oncology group. Leuk Lymphoma. 2005;46: 681-691.
13. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992;80:2735-2739.
14. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
15. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122-3133.
16. Steinherz PG, Gaynon P, Miller DR, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen-a new intensive therapy protocol: a report from the childrens cancer study group. J Clin Oncol. 1986;4:744-752.
17. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 1994;8:968-973.
18. Nuessler V, Gullis E, Pelka-Fleischer R, et al. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients. Ann Hematol. 1997;75(1-2):17-26.
19. Ludescher C, Eisterer W, Hilbe W, et al. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia. 1995;9:350-356.
20. Hedley DW, Xie SX, Minden MD, et al. A novel energy dependent mechanism reducing daunorubicin accumulation in acute myeloid leukemia. Leukemia. 1997;11:48-53.
21. Rosati A, Candussio L, Crivellato E, et al. Bodipy-FL-verapamil: a fluorescent probe for the study of multidrug resistance proteins. Cell Oncol. 2004;26(1-2):3-11.
22. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003;10:159-165.
23. Lamy T, Drenou B, Grulois I, et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia. 1995;9:1549-1555.
24. Leith CP, Chen IM, Kopecky KJ, et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multi-parameter flow cytometry: identification of discordant MDR-/ efflux+ and MDR1+/efflux- cases. Blood. 1995;86:2329-2342.
25. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56: 3010-3020.
26. Georges E, Bradley G, Gariepy J, et al. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA. 1990;87:152-156.
27. Paietta E, Andersen J, Racevskis J, et al. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group. Blood Rev. 1995;9:47-52.
28. Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17:818-824.
29. Schrappe M, Arico M, Harbott J, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92:2730-2741.
30. Kaspers GJ, Pieters R, Klumper E, et al. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma. 1994; 13(3-4):187-201.
31. Maillefert JF, Maynadie M, Tebib JG, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol. 1996;35: 430-435.
32. Gruol DJ, Bourgeois S. Chemosensitizing steroids: glucocorti-coid receptor agonists capable of inhibiting P-glycoprotein function. Cancer Res. 1997;57:720-727.